cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
Sixteen patients with advanced non-small-cell lung cancer were treated with the combination of cis-platinum, 5-fluorouracil, and hydroxyurea. There were two complete responses (lasting 16 weeks each) and one partial response (lasting 12 weeks). Toxicity was manageable, but responders were unable to tolerate further therapy. Despite the obtaining of complete responses, the overall benefit of this particular combination requires further clinical investigation.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage*; D004341:Drug Evaluation; D004357:Drug Synergism; D004361:Drug Tolerance; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged
D002945:Cisplatin; D005472:Fluorouracil; D006918:Hydroxyurea